I don't make too many recos, but I began a scaled-in buy of AVEO on today's drop. Though I'm a fan of MET inhibition, I'm not a big fan of Tivozanib. I started buying today on the strength of their p2 MAB research. I encourage all to take a look. I think they took an unwarranted hit today.
Eerie looking at that one group on the Tivozanib's chemical structure is so similar to one on Cabo. (I'm well aware though that a minute differences make all the difference in the world when it comes to chemical binding.)
Wildbiftek, I regard you as a very astute biotech player. Your contributons here are notable, your MB posture one of honest endeavor, and your contempt toward MB falsity a match of my own. If you have perceptions to share on AVEO, I'd love to hear them.
My buy-in today on a 48% drop was mainly for the near term bounce, but I regard AVEO as a player.